New cancer drugs
Tovorafenib approved by the FDA: breakthrough treatment for low-grade glioma in children with BRAF mutation
The FDA accelerated the approval of Tovorafenib (Ojemda) for the treatment of low-grade gliomas in children with recurrent or refractory BRAF variants on April 23, 2024. This article introduces its efficacy data and safety in detail. . .
Read more >>
A new generation of Menin inhibitors revolutionizes the treatment of acute leukemia, giving Hong Kong patients new hope
The 2024 Annual meeting of the American Society of Hematology will reveal the safety and efficacy of a new generation of Menin inhibitors in the treatment of acute myeloid leukemia (AML). Ziftomenib, Bleximenib and other drug needles. . .
Read more >>
Retifanlimab-dlwr is used to treat metastatic or recurrent locally advanced Merkel cell carcinoma
The U.S. FDA accelerated the approval of the PD-1 antibody retifanlimab-dlwr for the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma in March 2023. POD1UM-201 clinical trial. . .
Read more >>
Zenocutuzumab: FDA approves new bispecific antibody for the treatment of NRG1 gene fusion cancer
Zenocutuzumab was approved by the U.S. FDA for the treatment of patients with lung cancer and pancreatic cancer with NRG1 gene fusion, marking a breakthrough in cancer treatment.
Read more >>
The U.S. Food and Drug Administration (FDA) approved the IDH1/2 inhibitor Vorasidenib for patients with specific astrocytoma or oligodendrocytoma
The U.S. FDA approved the IDH1/2 inhibitor Vorasidenib for use in patients with specific astrocytoma and oligodendrocytoma in August 2024. INDIGO clinical trials have shown that it significantly prolongs life without progress. . .
Read more >>Immunotherapy combined with chemotherapy for the treatment of advanced gastric cancer/gastroesophageal junction adenocarcinoma: Analysis of the results of DURIGAST PHASE II trial
Research overview French multicenter non-controlled phase II clinical trial (PROD
Read more >>FDA accelerated approval of Tovorafenib for the treatment of low-grade glioma patients with recurrent or refractory BRAF gene variants in children
The FDA accelerated the approval of the RAF inhibitor Tovorafenib (Ojemda) in April 2024 for the treatment of patients with recurrent/refractory low-grade glioma in children carrying BRAF gene variants. FIREF. . .
Read more >>Menin inhibitor Revumenib shows curative effect in KMT2A rearranged relapsed/refractory acute leukemia
The Menin inhibitor Revumenib showed a significant effect on KMT2A rearrangement in patients with relapsed/refractory acute leukemia in the AUGUST-101 study, with A complete remission rate of 22.8%, overall. . .
Read more >>
The U.S. FDA accelerated the approval of Retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma
The U.S. FDA accelerated the approval of the PD-1 inhibitor Retifanlimab-dlwr (Zynyz) for the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma on March 22, 2024. PODI. . .
Read more >>